Collegium Pharmaceutical, Inc.
corporate_fare Company Profile
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for COLL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for COLL spans 10-Q, 8-K, 8-K/A, 10-K.
Recent high-impact activity:
- Collegium 10-Q: Q3 Net Income $21.8M, EPS $0.60, $1.1B Debt Load Detailed
- Collegium Q3'26: Record $216.3M Revenue, EPS $0.60, 2026 Guidance Reaffirmed
- Collegium Posts 3Q EPS of 60 Cents
- Collegium Pays $17M to End Nucynta Patent Fight With Grünenthal
- Collegium Pays $17M to Settle Nucynta Patent Suit and End Grünenthal Royalties
Financial Snapshot
Short Interest & Short Volume
9.40 days to coverFINRA reported short interest of 5,194,875 shares in COLL as of the October 30, 2026 settlement, a 3.4% decrease from the prior period — about 9.4 days to cover at its recent average daily volume. On November 20, 2026, 51.0% of COLL volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.